文献速递湿疹皮炎与荨麻疹

Lebrikizumab联合外用糖皮质激素治疗中重度特应性皮炎青少年和成人的疗效与安全性:随机临床试验(ADhere)

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
PubMed 文献 · JAMA Dermatol · 2023-01-01

ADhere是一项16周随机、双盲、安慰剂对照、多中心3期试验,纳入211例中重度特应性皮炎青少年和成人,比较Lebrikizumab联合低至中效外用糖皮质激素与安慰剂联合外用糖皮质激素。第16周时,Lebrikizumab联合组IGA(0,1)应答率和EASI-75应答率均显著高于安慰剂联合组,安全性与既往报告一致。

要点

  • 第16周IGA(0,1)应答率:Lebrikizumab联合组41.2% vs 安慰剂联合组22.1%(P = .01)。
  • 第16周EASI-75应答率:Lebrikizumab联合组69.5% vs 安慰剂联合组42.2%(P < .001)。
  • Lebrikizumab联合组常见治疗中出现的不良事件包括结膜炎、头痛、高血压、注射部位反应和疱疹感染。

核心结论

  • 在中重度特应性皮炎青少年和成人中,Lebrikizumab联合外用糖皮质激素较单用外用糖皮质激素与更好的结局相关,安全性与此前报告的特应性皮炎试验一致。

研究设计与样本

  • ADhere是一项16周随机、双盲、安慰剂对照、多中心3期临床试验,于2020年2月3日至2021年9月16日在德国、波兰、加拿大和美国的54个门诊中心开展。
  • 共211例患者按2:1比例随机接受皮下Lebrikizumab(基线及第2周负荷剂量500 mg,此后每2周250 mg)或安慰剂每2周一次,均联合外用糖皮质激素,治疗16周。

主要发现

  • 第16周达到IGA(0,1)且较基线改善≥2分的患者比例:Lebrikizumab联合组41.2% vs 安慰剂联合组22.1%(P = .01)。
  • 第16周达到EASI-75的患者比例:Lebrikizumab联合组69.5% vs 安慰剂联合组42.2%(P < .001)。
  • Lebrikizumab联合组在所有关键次要终点均显示统计学显著改善。
  • 大多数治疗中出现的不良事件为非严重、轻或中度,未导致研究终止。
  • Lebrikizumab联合组报告频率较高的治疗中出现的不良事件包括结膜炎(4.8%)、头痛(4.8%)、高血压(2.8%)、注射部位反应(2.8%)和疱疹感染(3.4%),安慰剂联合组患者报告频率≤1.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Lebrikizumab (LEB), a high-affinity monoclonal antibody targeting interleukin (IL)-13, demonstrated efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD) during 16 weeks of monotherapy in a phase 2b trial, and two 52-week phase 3 trials. OBJECTIVE: To evaluate efficacy and safety of LEB combined with low- to mid-potency topical corticosteroids (TCS) in patients with moderate-to-severe AD. DESIGN, SETTING, AND PARTICIPANTS: The ADhere trial was a 16-week randomized, double-blinded, placebo (PBO)-controlled, multicenter, phase 3 clinical trial conducted from February 3, 2020, to September 16, 2021. The study was conducted at 54 outpatient sites across Germany, Poland, Canada, and the US and included adolescent (aged ≥12 to <18 years weighing ≥40 kg) and adult patients with moderate-to-severe AD. The treatment allocation ratio was 2:1 (LEB:PBO). INTERVENTIONS: Overall, 211 patients were randomized to subcutaneous LEB (loading dose of 500 mg at baseline and week 2, followed by 250 mg every 2 weeks [Q2W] thereafter) or PBO Q2W in combination with TCS for 16 weeks. MAIN OUTCOMES AND MEASURES: Efficacy analyses at week 16 included proportions of patients achieving Investigator's Global Assessment score of 0 or 1 (IGA [0,1]) with 2 or more points improvement from baseline, and 75% improvement in the Eczema Area and Severity Index (EASI-75). Key secondary end points included evaluation of itch, itch interference on sleep, and quality of life. Safety assessments included monitoring adverse events (AEs). RESULTS: The mean (SD) age of patients was 37.2 (19.3) years, 103 (48.8%) patients were women, 31 (14.7%) patients were Asian, and 28 (13.3%) patients were Black/African American. At week 16, IGA (0,1) was achieved by 145 (41.2%) patients in the LEB+TCS group vs 66 (22.1%) receiving PBO+TCS (P = .01); corresponding proportions of patients achieving EASI-75 were 69.5% vs 42.2% (P < .001). The LEB+TCS group showed statistically significant improvements in all key secondary end points. Most treatment-emergent adverse events (TEAEs) were nonserious, mild or moderate in severity, and did not lead to study discontinuation. The TEAEs frequently reported in the LEB+TCS group included conjunctivitis (7 [4.8%]), headache (7 [4.8%]), hypertension (4 [2.8%]), injection site reactions (4 [2.8%]), and herpes infection (5 [3.4%]) vs 1.5% or less patient-reported frequencies in the PBO+TCS group. Similar frequencies of patient-reported serious AEs following LEB+TCS (n = 2, 1.4%) and PBO+TCS (n = 1, 1.5%). CONCLUSIONS AND RELEVANCE: In this randomized phase 3 clinical trial, LEB+TCS was associated with improved outcomes in adolescents and adults with moderate-to-severe AD compared with TCS alone, and safety was consistent with previously reported AD trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04250337.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). JAMA Dermatol. 2023. PMID: 36630140. doi:10.1001/jamadermatol.2022.5534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。